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ABSTRACT
Drug-induced liver injury (DILI) is a significant clinical and economic problem in the United States, yet the mechanisms that
underlie DILI remain poorly understood. Recent evidence suggests that signaling molecules released by stressed
hepatocytes can trigger immune responses that may be common across DILI mechanisms. Extracellular vesicles released by
hepatocytes, principally hepatocyte-derived exosomes (HDEs), may constitute one such signal. To examine HDE alterations
as a function of drug-induced stress, this work utilized prototypical hepatotoxicant acetaminophen (APAP) in male
Sprague-Dawley (SD) rats, SD rat hepatocytes, and primary human hepatocytes. HDE were isolated using ExoQuick
precipitation reagent and analyzed by quantification of the liver-specific RNAs albumin and microRNA-122 (miR-122). In
vivo, significant elevations in circulating exosomal albumin mRNA were observed at subtoxic APAP exposures. Significant
increases in exosomal albumin mRNA were also observed in primary rat hepatocytes at subtoxic APAP concentrations. In
primary human hepatocytes, APAP elicited increases in both exosomal albumin mRNA and exosomal miR-122 without
overt cytotoxicity. However, the number of HDE produced in vitro in response to APAP did not increase with exosomal RNA
quantity. We conclude that significant drug-induced alterations in the liver-specific RNA content of HDE occur at subtoxic
APAP exposures in vivo and in vitro, and that these changes appear to reflect selective packaging rather than changes in
exosome number. The current findings demonstrate that translationally relevant HDE alterations occur in the absence of
overt hepatocellular toxicity, and support the hypothesis that HDE released by stressed hepatocytes may mediate early
immune responses in DILI.
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Drug-induced liver injury (DILI) is responsible for significant
pre- and post-market drug failures and is the primary cause of
acute liver failure in the United States and Europe (Bernal et al.,
2010; Ostapowicz et al., 2002; Wilke et al., 2007). DILI, therefore,
represents a major economic and clinical challenge for patients,
healthcare providers, and pharmaceutical companies.
Identification of underlying mechanisms has proved especially
difficult as DILI has been associated with hundreds of drugs
that elicit a broad spectrum of injuries (Hornby et al., 2014;
Hussaini and Farrington, 2014). However, increasing evidence
suggests that drug-induced hepatocellular death may often be
mediated by immune responses (Adams et al., 2010; Ju and
Reilly, 2012; Russmann et al., 2009). For example, human leuko-
cyte antigen genotype is a strong risk factor for DILI associated
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with a wide range of drugs, suggesting a role for the adaptive
immune system in drug-mediated hepatotoxicity (Urban et al.,
2014). In addition, elevations in biomarkers that trigger an in-
nate immune response such as high-mobility group box 1
(HMGB1), and those that are suggestive of immune cell activa-
tion including miR-155 and acetylated HMGB1, have been asso-
ciated with DILI (Antoine et al., 2014; Bala et al., 2012; Fontana,
2014). Furthermore, immune reactions are triggered by hepato-
cellular danger signals, which can be released in the absence of
hepatocyte death and communicate to other cell types as part
of a stress response (Uetrecht and Naisbitt, 2013).
Extracellular vesicles (EVs) released by hepatocytes, princi-
pally hepatocyte-derived exosomes (HDEs), may constitute one
such danger signal (Conde-Vancells et al., 2008; De Maio, 2011;
Royo and Falcon-Perez, 2012; Royo et al., 2013). By virtue of their
small size (<150 nm), HDE can readily cross through fenestra-
tions in the sinusoidal endothelium and enter the bloodstream
(Conde-Vancells et al., 2008), carrying liver-specific contents that
are modified during DILI (Wetmore et al., 2010). Clinically rele-
vant alterations in HDE content and quantity have been detected
in multiple models of liver injury including viral hepatitis (Zhang
et al., 2014), alcoholic hepatitis (Momen-Heravi et al., 2015b), non-
alcoholic steatohepatitis (Hirsova et al., 2016), cirrhosis, and he-
patocellular carcinoma (Bernal et al., 2010). Moreover, exosomes
are immunomodulatory and can carry damage-associated mo-
lecular patterns (DAMPs), antigens, and cytokines to recipient
cells (Beninson and Fleshner, 2014; De Maio, 2011; Liu et al., 2006;
Robbins and Morelli, 2014). In the liver, HDE released by hepatitis
C-infected hepatocytes activate dendritic cells and those re-
leased during lipotoxicity influence macrophage phenotype
(Dreux et al., 2012; Hirsova et al., 2016). Recent experiments have
demonstrated that one means by which HDE evoke immune re-
sponses is the delivery of functional genetic material such as
microRNA (miRNA) and messenger RNA (mRNA). For example,
HDE-based RNA species miR-122 and albumin mRNA (ALB) have
been shown to activate recipient monocytes and fibroblasts, re-
spectively (Momen-Heravi et al., 2015a; Royo et al., 2013).
HDE may play a critical role in the initiation of and response
to DILI by transmitting signals of hepatocellular stress that di-
rectly or indirectly stimulate an immune response. For HDE to
mediate early DILI events, we hypothesized that significant al-
terations in HDE content and/or number must occur prior to, or
in the absence of, overt hepatocellular injury. To better under-
stand the potential of HDE to modulate early immune-driven
DILI events, we sought to establish that subtoxic drug-induced
HDE alterations were consistent in vivo and in vitro, and relevant
in human DILI. Acetaminophen (APAP) was selected as the
model hepatotoxicant due to its well-defined in vivo and in vitro
toxicity profiles. We utilized this prototypical intrinsic hepato-
toxicant for verification that the exosomes released by hepato-
cytes following drug exposure were altered in the absence of
overt injury. Although the role of immune reactions in APAP-in-
duced liver injury is controversial, there is recent evidence of in-
duction of immune tolerance in healthy adults that do not
develop alanine aminotransferase (ALT) elevations after recur-
rent therapeutic doses of APAP (Fannin et al., 2015), further sup-
porting selection of APAP as our model toxicant. This finding
also suggests that some stress-induced HDE alterations may pro-
mote an adaptive response to toxicity rather than an exacerba-
tion of injury.
We therefore evaluated the dose- and time-dependent ef-
fects of APAP on HDE-associated RNAs in rats, primary rat hepa-
tocytes, and primary human hepatocytes. Because exosomes in
the blood are derived from multiple cell types, exosome-
associated liver-enriched ALB mRNA and liver-specific miR-122
were assayed as a means to confirm the presence of, and track
alterations in, HDE across platforms (Bandiera et al., 2015;
Miyamoto et al., 2008).
MATERIALS ANDMETHODS
Animal Exposures
Male Sprague-Dawley rats (Crl:SD), 7–9 weeks of age, were pur-
chased from Charles River Laboratories and allowed to accli-
mate in-house for 7–10 days prior to study initiation. Water and
food (pelleted PicoLab Rodent Diet 20 [Lab Diet]) were available
ad libitum during this time. Food was removed during an 18 h
fasting period immediately prior to compound administration.
APAP (Sigma-Aldrich) was administered in 0.5% (w/v) methyl-
cellulose (Sigma-Aldrich) at 0, 500, or 1400 mg/kg by oral gavage.
After dosing, food was provided ad libitum until necropsy.
Studies were conducted in accordance with the Guide for the
Care and Use of Laboratory Animals, and were approved by the
Mispro Institutional Animal Care and Use Committee (Mispro
Biotech Services, Inc.).
Necropsy and Histology
Rats were euthanized by CO2 inhalation and subsequent exsan-
guination at 0, 1, 2, 4, 8, 12, and 24 h post-dose (n¼ 6 per group).
Blood was collected in K2EDTA Vacutainer tubes (Becton
Dickinson). Portions of the liver (median lobe) were minced and
placed in RNAlater Stabilization Solution (Applied Biosystems)
for gene expression analysis. Sections from the left and median
lobes were fixed in 10% neutral buffered formalin followed by
70% ethanol. Paraffin-embedded blocks were sectioned (5 mm)
and stained with hematoxylin and eosin (H&E). Histopathological
examination was performed by a board-certified veterinary pa-
thologist. Severity scores were assigned for centrilobular degen-
eration and necrosis (þ1, minimal;þ2, mild;þ3, moderate;þ4,
marked). Degeneration was defined as prenecrotic hepatocellular
change in centrilobular areas, including cytoplasmic hypereosi-
nophilia, nuclear condensation, and cellular dissociation.
Degeneration is assumed to precede fulminant necrosis such
that, if given more time, degenerating cells likely would have
progressed to necrosis. Necrosis was marked by areas of com-
plete hepatocellular destruction and neutrophil infiltration.
Plasma Isolation and Plasma-Derived Exosome
Enrichment
Within 15 min of collection, blood was centrifuged to obtain cell-
free plasma. ALT activity in fresh plasma was determined using a
CLC 720 clinical chemistry analyzer (Carolina Liquid Chemistries).
Additional aliquots of plasma were frozen at 80C until exosome
isolation. Thawed plasma was treated with Purified Thrombin
Plasma Reagent and exosomes were isolated with ExoQuick
Exosome Precipitation Solution (System Biosciences) according to
the manufacturer’s instructions. The post-ExoQuick supernatant
was reserved for RNA isolation to analyze liver-specific RNAs in
the extra-exosomal, protein-rich plasma fraction.
Primary Hepatocyte Culture and Medium-Derived
Exosome Enrichment
Freshly isolated primary hepatocytes from human donors (n¼ 7;
Table 1) and male SD rats (n¼ 3) were obtained from commercial
sources (QPS Hepatic Biosciences and Triangle Research Labs).
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Individual batches of fresh hepatocytes were seeded into 12-
well plates coated with collagen type I (Corning) at a density
of 0.9  106 cells per well in hepatocyte plating medium
(William’s E medium, penicillin-streptomycin, GlutaMax,
HEPES, sodium pyruvate, fetal bovine serum [Thermo Fisher
Scientific], insulin, and dexamethasone [Sigma-Aldrich]).
Culture plates were incubated at 37C with 5% CO2. After at-
tachment, nonadherent cells were removed and fresh plating
medium was added. Cultures were transitioned to hepato-
cyte maintenance medium without fetal bovine serum after
3–4 h. Following a 24-h acclimation period, hepatocyte cul-
tures were exposed to APAP or a medium control (vehicle) for
24 h. All conditions were tested in triplicate culture wells for
each rat or human donor.
Hepatocyte-conditioned medium (1–2 ml) was collected
after 24 h and clarified by centrifugation at 3000 g for 15 min.
Exosomes were precipitated from medium with ExoQuick-TC
(System Biosciences) following the protocol for this sample
type. Lactate dehydrogenase (LDH) activity was assayed with
a Cytotoxicity Detection Kit (Roche) as described previously
in Kia et al. (2015). Cellular ATP content was measured with
CellTiter-Glo Luminescent Cell Viability Assay (Promega) ac-
cording to the manufacturer’s instructions. Data were col-
lected using a SpectraMax M3 microplate reader (Molecular
Devices).
EV Characterization and Validation of Exosome
Enrichment
Nanoparticle tracking analysis
Nanoparticle tracking analysis was performed on exosomes
produced in vitro using a NanoSight NS500 (Malvern
Instruments). The instrument was calibrated using polystyrene
bead standards (100 nm) before each use (Malvern Instruments).
Diluted samples were advanced through the detection chamber
to obtain 5 readings per sample, each with a capture period of
60 s. Particle concentration and size were determined using
NTA software version 3.0 (Malvern Instruments).
Electron microscopy
Exosomes were precipitated from filtered (0.2 mm PES) hepato-
cyte-conditioned culture medium using ExoQuick-TC. Exosome
preparations were diluted 1:1000 in Dulbecco’s phosphate buff-
ered saline to start the assembly reaction. At 10 min, samples
were applied to glow-discharged 200 mesh Quantifoil R 2/1 grids
(Electron Microscopy Sciences), blotted briefly, and plunged into
liquid ethane as described previously (Dokland, 2006). The fro-
zen grids were transferred to a Gatan 622 cryo-holder and im-
aged using an FEI Tecnai F20 transmission electron microscope,
operated at 200 kV with magnifications from 5000 to 29 000
and defocus settings of 6.0 to 10.0 lm. Images were collected
on a Gatan Ultrascan 4000 CCD camera.
Immunoblot analysis
Protein extracts were prepared from hepatocyte monolayers or
exosomes using RIPA Lysis and Extraction Buffer (Thermo) with
Halt Protease Inhibitor Single-Use Cocktail (Thermo), and Triton
X-100 (hepatocytes only). Protein concentration was determined
using the BCA Protein Assay Kit (Thermo). Equal protein quanti-
ties of each sample were separated on 4–12% NuPAGE Bis-Tris
gels (Life Technologies) and transferred to Immobilon-FL PVDF
membranes (Millipore). Membranes were blocked with either
5% (w/v) nonfat dry milk in PBS or Odyssey PBS Blocking Buffer
(Licor Biosciences). The following primary antibodies were used
for immunoblotting: Flotillin-1 (BD Transduction Laboratories),
CD63 (Abcam), CD81 (AbD Serotech), Prohibitin-1 (Santa Cruz
Biotechnology Inc.), and Grp78 (BD Transduction Laboratories).
Proteins were detected using IRDye secondary antibodies (Licor
Biosciences) or Alexa Fluor 680-conjugated AffiniPure IgG
(Jackson Immunoresearch Laboratories). Blots were imaged us-
ing an Odyssey Classic Imaging System (Licor Biosciences).
Total RNA Isolation and Analysis by Absolute qRT-PCR
Total RNA was isolated from plasma- and culture medium-de-
rived exosomes using the miRCURY Cell & Plant Isolation Kit
(Exiqon) according to the manufacturer’s instructions for RNA
isolation from blood. To analyze extracellular RNA in the pro-
tein-rich compartment of culture medium and plasma, total
RNA was isolated from culture medium samples or post-
ExoQuick plasma supernatants, respectively, using the
miRNeasy Serum/Plasma Kit (Qiagen) and manufacturer’s pro-
tocol. Total RNA from rat liver, rat hepatocytes, and human he-
patocytes was isolated with the miRNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions. For all RNA isola-
tions, a spike-in cocktail consisting of linear acrylamide carrier
(Applied Biosystems) and exogenous RNA controls, Luciferase
mRNA mimic (Promega) and Caenorhabditis elegans miR-39
(Qiagen), was added.
Synthesis of cDNA for mRNA analysis was performed with
equal volumes of RNA using a High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). RT-PCR was performed
on a 7900HT Fast RT-PCR System (Applied Biosystems) using
TaqMan Gene Expression Assays and Fast Advanced Master
Mix. Absolute quantities of mRNAs were calculated using a spe-
cies-matched standard curve generated from bacterial plasmids
or PCR amplification of liver cDNA. Synthesis of cDNA for analy-
sis of miR-122 copy number was performed using a TaqMan
miRNA Reverse Transcription Kit (Applied Biosystems).
Absolute qRT-PCR was performed on a 7900HT Fast RT-PCR
System (Applied Biosystems) using TaqMan miRNA Assays
(hsa-mir-122-5p) and Universal Master Mix II (no UNG).
Absolute quantities of miR-122 in cells, exosomes, and the pro-
tein-rich fraction were computed from a standard curve of syn-
thetic miR-122 cDNA.
Statistical Analysis
Analyses were conducted using GraphPad Prism 6 (GraphPad
Software, Inc.) unless otherwise noted. For all tests, p< 0.05 was
considered statistically significant. Mean values from plasma-
based endpoints (i.e. exosomal RNA and ALT activity) were ana-
lyzed using a 2-way analysis of variance (ANOVA). Results from
APAP-treated animals were compared with time-matched con-
trol groups with Fisher’s Least Significant Difference (Fisher’s
LSD) test. In vitro data from rat hepatocytes were averaged
across triplicate wells and a fold change relative to control was
calculated for each rat. Fold changes across rats (n¼ 3) were av-
eraged and compared by 1-way ANOVA. Results from each
TABLE 1. Characteristics of primary human hepatocyte donors
Age (year) BMI Sex Race
<1 15 M African-American
3 17 M Caucasian
14 24 F Caucasian
26 32 M Caucasian
30 33 F African-American
48 24 F Caucasian
74 23 F Caucasian
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APAP concentration were compared with controls using
Dunnett’s test for multiple comparisons. In vitro data from each
human hepatocyte batch were averaged across triplicate wells
and a fold change relative to donor-matched controls was calcu-
lated. From individual fold changes, a mean across all donors
was obtained. Mean fold changes of control and APAP-treated
groups were compared by Student’s 2-tailed t-test.
RESULTS
Exosomal Albumin Transcript Quantities Are
Significantly Elevated Prior to APAP-Induced
Hepatic Necrosis in Rats
Adult male SD rats were administered a low (500 mg/kg) or high
(1400 mg/kg) dose of APAP or a vehicle control and were sacri-
ficed at 0, 1, 2, 4, 8, 12, or 24 h post-dose. Liver injury was deter-
mined by histology and plasma ALT activity. Liver-specific
RNAs isolated from circulating exosomes were quantified to
determine the relationship between HDE alterations and liver
injury. Histological findings of necrosis (Figs. 1A–D;
Supplementary Table 1) and elevated plasma ALT activity
(Figure 2A, Supplementary Figure 1A) were observed only in rats
treated with the high dose of APAP at 24 h post-exposure.
Exosomal albumin transcript (ALB) quantity, however, was sig-
nificantly elevated in APAP-treated animals (relative to time-
matched, vehicle-treated controls) prior to histological observa-
tions of necrosis or increases in plasma ALT (Figure 2B,
Supplementary Figure 1B). Drug-induced elevations in mean
exosomal ALB quantity were detected as early as 4 h post-dose;
these elevations became dose-dependent at 8 h post-dose. By
12 h, mean exosomal ALB mRNA had increased 30- and 50-fold
in the low- and high-dose groups, respectively (Figure 2B).
Increases in exosomal ALB reached statistical significance in
the high dose group at 12 h and in the low dose group at 24 h,
without signs of liver injury (Figure 2B, Supplementary Figure
1B). Together, these data suggest that changes in HDE release
occur as a result of subtoxic APAP exposure in vivo.
Quantity and Distribution of Extracellular miR-122 Are
Altered by Subtoxic APAP Exposure In Vivo
Unlike ALB mRNA which was not detected outside of the exoso-
mal plasma fraction (data not shown), circulating miR-122 is
stable in exosomes and in a ‘protein-rich’ Argonaute-bound
form (Arroyo et al., 2011; Hornby et al., 2014). In order to deter-
mine if miR-122 followed a similar trend as exosomal ALB upon
in vivo APAP exposure, we measured exosomal and protein-rich
fractions of circulating miR-122. A trend toward increased exo-
somal miR-122 was observed in APAP-treated animals at 8 h
post-dose (Figure 3A, Supplementary Figure 1C). This trend con-
tinued, with mean levels reaching 3- and 4-fold over controls in
the low- and high-dose groups at 12 h, respectively. At 24 h
post-dose, mean exosomal miR-122 quantities in the low-dose
group reached 9-fold that of vehicle-treated controls, despite a
lack of hepatocellular toxicity. MiR-122 in the protein-rich frac-
tion showed trends similar to exosomal miR-122 but was signif-
icantly elevated in the low-dose group after 24 h (Figure 3B,
Supplementary Figure 1D). Whereas the content of miR-122 in
both exosomal and protein-rich compartments was increased
FIG. 1. Histopathology of rat liver sections 24 h after APAP treatment. Representative photomicrographs of H&E stained liver sections from rats 24 h after administra-
tion of (A) 0.5% methylcellulose vehicle, (B) 500 mg/kg APAP, or 1400 mg/kg APAP with (C) moderate or (D) marked centrilobular necrosis. Bars indicate 200 mm.
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by APAP exposure in our study, the distribution of miR-122 be-
tween these plasma compartments shifted over time. In the
high-dose group, the percentage of circulating miR-122 within
HDE decreased over time and reached statistical significance at
12 h, prior to overt liver injury (Figure 3C).
Unexpectedly, we observed previously undocumented
dose-dependent decreases in exosomal and protein-rich
miR-122 fractions after 2 h of APAP exposure, which were not
accompanied by decreases in exosomal ALB (Figure 3D). To
determine whether the decreases in exosomal miR-122 re-
flected selective packaging of RNA into HDE or decreased he-
patocyte miR-122 content, we quantified miR-122 in liver
tissue obtained from the 2 h post-exposure animals. There
was a trend toward increased hepatic miR-122 copy number
FIG. 2. In vivo elevations in ALT activity and exosomal ALB as a function of APAP dose and exposure time. APAP-induced elevations in (A) plasma ALT activity and (B)
exosomal ALB mRNA. Data are presented as mean þ SEM of fold change over time-matched controls (n ¼ 5–6 rats/group). *p < 0.05, ****p < 0.0001; 2-way ANOVA with
Fisher’s LSD.
FIG. 3. Alterations in exosomal and protein-rich fractions of miR-122 after in vivo APAP exposure. Fold change in (A) exosomal and (B) protein-rich miR-122 plasma compart-
ments relative to time-matched vehicle controls (n ¼ 5–6 rats/group). *p < 0.05, **** p < 0.0001; 2-way ANOVA with Fisher’s LSD. (C) Percentage of circulating miR-122 in HDE
from 1400 mg/kg APAP-treated rats. *p < 0.05, ***p < 0.001; 1-way ANOVA with Dunnett’s post-test relative to t ¼ 1 h. (D) Relationship between liver-specific RNAs measured
in exosomes and liver tissue at 2 h post-dose. *p < 0.05; 1-way ANOVA with Dunnett’s post-test relative to vehicle. Data are presented as mean þ SEM.
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coincident with statistically significant dose-dependent de-
creases in exosomal miR-122 (Figure 3D). Exosomal ALB,
however, was not significantly affected in circulating exo-
somes or liver tissue (Figure 3D).
EV Preparations From Primary Rat and Human
Hepatocyte Cultures Are Highly Enriched for Exosomes
We selected a well-characterized exosome enrichment method
for our in vivo studies, and evidence suggests that most EVs re-
leased by hepatocytes are exosomal in size (Giugliano et al.,
2015; Koeck et al., 2014; Momen-Heravi et al., 2015a; Royo et al.,
2013). However, multiple cell types and tissues contribute to the
population of circulating vesicles, and therefore we could not
study the nature of hepatocyte-specific vesicles isolated from
the in vivo samples. To confirm the presence of exosomes in EVs
isolated by ExoQuick, we analyzed the size, morphology, and
protein enrichment of EVs produced in vitro by primary rat and
human hepatocytes.
EVs were isolated from conditioned medium of untreated
primary rat or human hepatocytes by ExoQuick-TC polymer
precipitation. Nanoparticle tracking analysis of rat and human
EV preparations revealed a majority of small exosome-sized
particles <200 nm in diameter, with the greatest concentration
of particles being <100 nm in size (Figs. 4A and B). These results
were confirmed using a ZetaView instrument (ParticleMetrix)
(data not shown). Cryo-electron microscopy verified exosome
enrichment in precipitated rat and human EV preparations,
which contained circular membrane-bound vesicles smaller
than 100 nm (Figs. 4C and D). Western immunoblot analyses of
rat EVs confirmed the presence of exosomal protein markers
CD81 and CD63 (Figure 4E). Prohibitin-1, a mitochondrial mem-
brane protein, was detected in rat hepatocytes but was not pre-
sent in rat HDE, suggesting a lack of cellular contamination in
exosomal samples (Figure 4E). Human EV preparations were
positive for exosomal markers CD63 and Flotillin-1 and did not
contain detectable cellular contamination, as measured by
Prohibitin-1 and Grp78, a protein found in the endoplasmic re-
ticulum (Figure 4F). These results confirm that our ExoQuick
preparations contain mostly HDE.
Subtoxic APAP Exposure Elicits Exosomal RNA
Elevations in Primary Rat Hepatocytes
To further characterize HDE release from drug-treated hepa-
tocytes, we explored whether APAP-dependent changes in
exosomal RNA content observed in vivo could be reproduced
in monocultures of primary rat hepatocytes. Primary rat he-
patocytes were exposed to a concentration range of APAP (0–
30 mM) for 24 h. Across 3 rat hepatocyte batches, statistically
significant elevations in LDH leakage and decreases in cellu-
lar ATP were not observed at concentrations <30 mM APAP
(Figure 5A). However, statistically significant increases in
exosomal ALB mRNA were evident at concentrations as low
as 1.1 mM APAP (Figure 5B). Hepatocellular ALB levels were
not altered significantly at any APAP concentration, suggest-
ing that increased exosomal ALB was not a result of in-
creased expression at the cellular level. In contrast to our
in vivo findings, miR-122 was not elevated significantly in the
exosome- or protein-rich fractions prior to the onset of overt
cytotoxicity (Figure 5C).
We then tested the hypothesis that liver-specific exosomal
RNA levels are indicative of HDE number, which cannot cur-
rently be assessed in vivo. We performed nanoparticle tracking
analysis on HDE from primary rat hepatocyte cultures exposed
to 0, 10, or 30 mM APAP for 24 h (n¼ 2 rats). No statistically sig-
nificant changes in HDE quantity were observed at any concen-
tration (Figure 5D).
Increased Secretion of Exosomal RNA in the Absence of
Overt APAP Toxicity Translates to Primary Human
Hepatocyte Cultures
To determine whether primary human hepatocytes would re-
spond to APAP exposure by increasing production of exosomal
RNAs, we separately exposed individual batches of freshly iso-
lated primary hepatocytes (n¼ 7 donors) to a subtoxic APAP con-
centration (10 mM) for 24 h (Figure 6A). APAP treatment caused
increases in mean exosomal ALB (not statistically significant)
and miR-122 (p< 0.001) levels in the absence of overt injury
(Figs. 6B and C). Quantities of ALB and miR-122 in cells and pro-
tein-rich medium fractions were not affected by APAP exposure
(Figs. 6B and C).
To define the relationship between drug-induced changes
in liver-specific exosomal RNA and HDE number in a human
system, nanoparticle tracking analysis was performed on
exosomes isolated from control and treated (0 vs 10 mM
APAP) primary human hepatocyte cultures (n¼ 4 donors). As
observed in the rat experiments, APAP exposure did not
cause statistically significant changes in exosome quantity
(Figure 6D).
FIG. 4. Characterization of exosome enrichment in EVs secreted by primary rat
and human hepatocytes. Representative nanoparticle tracking analyses illus-
trating the average size distribution (þ SEM) of EVs isolated from untreated (A)
rat and (B) human hepatocyte-conditioned culture medium. Representative
cryo-electron micrographs of (C) rat and (D) human hepatocyte-derived EV prep-
arations. Bars indicate 100 nm. Western blot analysis of exosomal and cellular
markers in (E) rat and (F) human HDE (‘Ex’) relative to hepatocytes (‘Cell’).
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Establishing Baseline Quantities of Liver-Specific RNAs
in Exosomes From Primary Human Hepatocytes
Individual lots of primary human hepatocytes (n¼ 7) were cul-
tured for 24 h with or without 10 mM APAP. Substantial donor-
to-donor variability in the exosomal quantities of ALB and miR-
122 was apparent. To identify donor characteristics that poten-
tially influenced exosomal content, we related characteristics
such as sex, age, BMI, and race to the quantity of liver-specific
exosomal RNAs from medium control- and APAP-treated hepa-
tocytes (Supplementary Figure 2A). No association reached sta-
tistical significance, but we observed a relationship between
exosomal ALB and BMI (p¼ 0.074, regression analysis) in
untreated hepatocytes (Supplementary Figure 2B).
In an effort to establish healthy ranges of exosomal ALB and
miR-122, we examined absolute copy numbers of these exoso-
mal RNAs across hepatocyte donors (n¼ 7) under control condi-
tions. We found that quantities of exosomal miR-122 generally
corresponded with levels of protein-rich miR-122, although this
relationship did not hold true for every donor (Supplementary
Figure 3A). We did not observe a consistent relationship be-
tween exosomal and cellular ALB. Absolute copy numbers
of exosomal miR-122 ranged from approximately 107–109,
while exosomal ALB ranged from approximately 103–106
(Supplementary Figs. 3A and B).
Additional Liver-Enriched Transcripts Are Present in
Human HDEs
Finally we sought to confirm that additional liver-enriched
mRNAs previously identified in rat EVs, and enriched in both rat
and human liver, were packaged within human HDE (Miyamoto
et al., 2008; Okubo et al., 2013; Royo et al., 2013; Yu et al., 2010).
Exosomes were precipitated from the culture medium of
untreated primary human hepatocytes (n¼ 3 donors), and exo-
somal transcripts were quantified by absolute qRT-PCR. All 7
liver-enriched transcripts were detected in human HDE under
control conditions, and although the absolute amounts varied,
the relative proportions of each mRNA across donors were con-
sistent (Figure 7).
DISCUSSION
To determine whether HDE could mediate the immune reac-
tions that occur without overt hepatotoxicity following drug ex-
posure, we tested the hypothesis that HDE content and/or
number would be altered by drug-induced hepatocellular stress
in the absence of cell death. We found that the RNA content of
HDE was affected prior to, and in the absence of, overt hepato-
cellular injury in rats receiving both toxic and subtoxic doses of
APAP. These results translated across experimental models and
species as similar phenomena were observed in primary hepa-
tocyte cultures from both rats and humans.
APAP was selected for this work largely for its defined toxic-
ity profile in vivo and in cultured hepatocytes from both rats and
humans. Although we are ultimately interested in the role of
exosomes in immune signaling, this study does not address the
consequences of the immune component of APAP-induced hep-
atotoxicity, a topic that remains controversial. Whether advan-
tageous (Antoniades et al., 2012; Jaeschke et al., 2012; Ju et al.,
2002; Williams et al., 2014) or damaging (Fannin et al., 2015;
Ferreira et al., 2016; Huebener et al., 2015; Tujios and Fontana,
2011), there is no question that inflammatory and immune re-
sponses are associated with APAP-induced hepatotoxicity in
FIG. 5. APAP-induced alterations in exosomes released by primary rat hepato-
cytes. Data are presented as mean þ SEM (n ¼ 3 rats) after 24 h APAP exposure.
(A) Cytotoxicity, as indicated by cellular ATP and LDH activity in medium. (B)
Exosomal and cellular levels of ALB in response to APAP. (C) miR-122 in exoso-
mal, protein-rich, and cellular fractions in response to APAP. *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001; 1-way ANOVA with Dunnett’s post-test relative to ve-
hicle. (D) Nanoparticle tracking analysis on HDE preparations from primary rat
hepatocytes (n ¼ 2 rats) after 24 h incubation with APAP. Data are presented as
the mean þ SEM of fold change in exosomes/ml relative to control. No statisti-
cally significant differences in exosome quantity between treated and untreated
groups were observed; 1-way ANOVA with Dunnett’s post-test relative to
vehicle.
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humans. In a study of recurrent therapeutic APAP dosing, acti-
vation of immune tolerance was evident in the peripheral blood
transcriptome of healthy adults without APAP-induced ALT
elevations (Fannin et al., 2015). This suggests that immune
responses after APAP exposure manifest prior to overt hepato-
cellular injury, a process that likely involves subtoxic hepatocel-
lular release of stress signals such as HDE.
Although mouse models are generally considered to be more
appropriate for the study of APAP-induced hepatotoxicity
mechanisms (Jaeschke et al., 2014; McGill et al., 2012), the goal of
the current work was to evaluate early changes in HDE that oc-
cur during APAP-induced stress, prior to hepatocellular injury.
Therefore, the rat was intentionally selected as a relatively re-
sistant preclinical species to extend the duration of APAP-
induced stress in vivo so that HDE alterations could be observed
prior to overt DILI. Evidence suggests that this latency may be
more similar to humans than the latency to fulminant hepato-
toxicity observed in mice (Jaeschke et al., 2014). Because mouse
hepatocytes are difficult to culture, selection of a rat model also
facilitated comparisons of data collected from primary hepato-
cytes relative to in vivo data from the same species.
In this study, we selected liver-specific exosomal contents
ALB mRNA and miR-122 as translational markers of HDE alter-
ation that also elicit immunologically relevant responses when
transferred to other cell types (Momen-Heravi et al., 2015a; Royo
et al., 2013). Circulating ALB mRNA and miR-122 have been iden-
tified previously as more sensitive and specific biomarkers of
liver injury in both preclinical species and humans (Antoine
et al., 2013; Okubo et al., 2013; Starckx et al., 2013; Wang et al.,
2009; Zhang et al., 2014). In particular, the value of miR-122 in
peripheral blood as a biomarker of APAP overdose is well estab-
lished (Antoine et al., 2013). Therefore, the biomarker potential
of miR-122 and HDE was not a focus of this work.
In our in vivo rat model of APAP-induced liver injury, the pro-
portion of plasma miR-122 contained within exosomes de-
creased over time in the high-dose group, presumably as a
function of increased hepatocellular damage. These data are in
agreement with what is known about the active nature of exo-
some release and the passive, necrotic release of protein-rich
miR-122 (Bobrie et al., 2011; Dear and Antoine, 2014; Kia et al.,
2015; Turchinovich et al., 2011, 2013; Villarroya-Beltri et al., 2014).
Similar shifts in miRNA localization between protein-rich and
exosomal fractions have been observed in DILI, and the nature
of these shifts may reflect different mechanisms of liver injury
(Bala et al., 2012, 2015). We propose that shifts in miRNA locali-
zation, such as those shown here, may serve a biological signal-
ing purpose. For example, miR-122 in HDE released by alcohol-
treated hepatocytes can prime monocytes for activation, while
biological activity has yet to be attributed to miRNA in the pro-
tein-rich form (Momen-Heravi et al., 2015a; Turchinovich et al.,
2013). Similarly, the effects of inflammatory mediators such as
Hsp70 are amplified when they are delivered to recipient cells
via exosomes (De Maio, 2011). While it is unlikely that exosomal
miR-122 is a driving factor or major inflammatory mediator in
overt APAP hepatotoxicity, during which necrosis releases mas-
sive amounts of DAMPs, the present miR-122 results support
the assertion that HDE alterations may be actively mediated
and functionally relevant in the early stages of hepatocyte
stress.
In vivo, parallel increases in HDE-associated ALB mRNA and
miR-122 were generally observed. However, exosomal ALB
mRNA did not decrease in vivo at early time points alongside
exosomal miR-122, providing evidence for the selective packag-
ing of RNA into HDE. Selective mRNA packaging into exosomes
FIG. 6. Alterations in exosomes released by primary human hepatocytes with
and without APAP exposure. (A) LDH leakage; (B) ALB mRNA; and (C) miR-122 af-
ter 24 h of exposure to APAP (10 mM). Data are presented as the mean þ SEM
across 7 donors. ***p < 0.001; Student’s t-test comparing treatment and control.
(D) Nanoparticle tracking analysis on HDE preparations from primary human
hepatocytes (n ¼ 4 donors) after 24 h incubation with APAP. Data are presented
as the mean þ SEM of fold change in exosomes/ml relative to control. No statis-
tically significant differences in exosome quantity between treated and
untreated groups were observed; Student’s t-test.
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has been observed in circulating vesicles from rats treated with
APAP or D-(þ)-galactosamine (DGAL), which contained distinct
transcript profiles suggestive of compound-specific exosomal
content (Wetmore et al., 2010). We confirmed these results with
HDE, as different trends in exosomal ALB mRNA and miR-122
were observed following APAP and DGAL exposures in primary
rat hepatocytes (Supplementary Figure 4). Although subtoxic
concentrations of DGAL elicited increases in both exosomal
RNAs, neither reached statistical significance prior to overt cy-
totoxicity. Our nanoparticle tracking results also recapitulate
the selective packaging hypothesis by indicating that the quan-
tity of exosomal RNA does not correspond to HDE number. As
such, the APAP-induced exosomal ALB mRNA elevations ob-
served in vivo and in vitro are likely the result of increased ALB
packaging within a similar number of HDE rather than an in-
crease in overall HDE production with constant ALB mRNA con-
tent. Although these findings are novel, it is important to note
that exosome quantification could be affected by the stability of
HDE in culture, which is currently unknown. Future experi-
ments to establish the half-life and clearance rate of HDE will be
imperative for understanding the biological implications of HDE
in DILI.
Although the intent of this work was not to study bio-
markers, by defining the kinetics and dose-dependence of HDE
release prior to overt DILI, this study could help to validate HDE
as sensitive, translational, and clinically relevant biomarkers of
DILI. We assayed 7 liver-enriched transcripts within primary
human HDE from 3 separate donors. To our knowledge, this is
the first characterization of the mRNA content of HDE from pri-
mary human hepatocytes. All 7 liver-enriched transcripts were
measurable, and there was some consistency in the relative
abundance of each transcript across the 3 donors, suggesting
that these mRNAs, originally detected in rat HDE (Miyamoto
et al., 2008; Okubo et al., 2013; Royo et al., 2013), may also be used
to identify human HDE. In addition, we have begun to define
normal levels of exosomal ALB mRNA and miR-122 across do-
nors. Despite the small donor pool, potential relationships were
identified between donor characteristics and exosomal content.
Continuing to study donor characteristics that influence HDE
RNA content and to define a healthy range of HDE-based RNA
levels will be important for interpreting biomarker data in the
future. These data will need to be considered in the context of
disease, which is known to affect basal HDE quantity and con-
tent. For instance, recent evidence suggests that high hepato-
cellular lipid content and nonlcoholic fatty liver disease
correspond to increased EV production by hepatocytes (Hirsova
et al., 2016; Kakazu et al., 2015).
In summary, we detected significant alterations in the liver-
specific RNA content of HDE at subtoxic doses of the prototypi-
cal hepatotoxicant APAP in rats and in primary rat and human
hepatocytes. These alterations appear to reflect differential
packaging of select RNAs in HDE rather than HDE number. The
changes in HDE content observed prior to and in the absence of
overt hepatocellular injury, together with growing data on the
role of exosomes in stimulating immune responses, support the
hypothesis that HDE released from drug-stressed hepatocytes
may transmit signals that mediate critical early immune re-
sponses across multiple forms of DILI. While this hypothesis
was substantiated using an intrinsic hepatotoxicant, future
work will address the release kinetics and signaling potential of
HDE released by hepatocytes exposed to idiosyncratic DILI
compounds.
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci.oxford
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